Werner Scheithauer

Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality

Guido Strunk, Robert Pirker, C. Marosi, 2015, Heart.

CADIAG-2/PANCREAS: An Artificial Intelligence System Based on Fuzzy Set Theory to Diagnose Pancreatic Diseases

Klaus-Peter Adlassnig, K. Adlassnig, W. Scheithauer, 1984 .

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Thomas Gruenberger, Laurence Collette, Peter M Schlag, 2008, The Lancet.

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

Thomas Gruenberger, Dietmar Tamandl, W. Scheithauer, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).

Michael Scholz, W. Scheithauer, M. Stauch, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).

Michael Scholz, Volker Heinemann, W. Scheithauer, 2013 .

Capecitabine as adjuvant treatment for stage III colon cancer.

Markus Abt, Joseph McKendrick, Marek Pawlicki, 2005, The New England journal of medicine.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Hartmut Link, Michael Scholz, Thomas Kirchner, 2014, The Lancet. Oncology.